Diagnostic use of autoantibodies in myasthenia gravis

References

• Aarli JA, Flood PR, Gilhus NE, Hofstad H, Matre R. Non-receptor striated muscle antibodies in sera from patients with myasthenia gravis. Monogr Allergy. 1988; 25:128–134.
   Google Scholar
• Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Arch Neurol. 2005; 62:442–446.
   PubMed Web of Science ®Google Scholar
• Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: Inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974; 186:55–57.
   PubMed Web of Science ®Google Scholar
• Aharonov A, Abramsky O, Tarrab-Hazdai R, Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet. 1975; 2:340–342.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976; 26:1054–1059.
   PubMed Web of Science ®Google Scholar
• Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci. 1983; 58:357–370.
   PubMed Web of Science ®Google Scholar
• Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psych. 1985; 48:1246–1252.
   PubMed Web of Science ®Google Scholar
• Luther MA, Schoepfer R, Whiting P, Casey B, Blatt Y, Montal MS, Montal M, Linstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J Neurosci. 1989; 9:1082–1096.
   PubMed Web of Science ®Google Scholar
• Voltz R, Hohlfeld R, Fateh-Moghadam A, Witt TN, Wick M, Reimers C, Siegele B, Wekerle H. Myasthenia gravis: Measurement of anti-AChR autoantibodies using cell line TE671. Neurology. 1991; 41:1836–1838.
   PubMedGoogle Scholar
• Somnier FE. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: The use of cell line TE671 as a source of AChR antigen. J Neuroimmunol. 1994; 51:63–68.
   PubMed Web of Science ®Google Scholar
• Beeson D, Amar M, Bermudez I, Vincent A, Newsom-Davis J. Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the epsilon subunit. Neurosci Lett. 1996; 207:57–60.
   PubMed Web of Science ®Google Scholar
• Beeson D, Jacobson L, Newsom-Davis J, Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology. 1996; 47:1552–1555.
   PubMed Web of Science ®Google Scholar
• Ohta K, Fujinami A, Saida T, Nishimura M, Kuno S, Ohta M. Frequency of anti-AChR epsilon subunit-specific antibodies in MG. Autoimmunity. 2003; 36:151–154.
   PubMed Web of Science ®Google Scholar
• Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol. 2005; 1:22–33.
   Google Scholar
• Hewer R, Matthews I, Chen S, McGrath V, Evans M, Roberts E, Nute S, Sanders J, Furmaniak J, Smith BR. A sensitive non-isotopic assay for acetylcholine receptor autoantibodies. Clin Chim Acta. 2006; 364:159–166.
   PubMed Web of Science ®Google Scholar
• Brooks EB, Pachner AR, Drachman DB, Kantor FS. A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: Positive results in “antibody-negative” myasthenia gravis. J Neuroimmunol. 1990; 28:83–93.
   PubMedGoogle Scholar
• Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001; 7:365–368.
   PubMed Web of Science ®Google Scholar
• McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004; 55:580–584.
   PubMed Web of Science ®Google Scholar
• Matthews I, Chen S, Hewer R, McGrath V, Furmaniak J, Rees Smith B. Muscle-specific receptor tyrosine kinase autoantibodies–a new immunoprecipitation assay. Clin Chim Acta. 2004; 348:95–99.
   PubMed Web of Science ®Google Scholar
• Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008; 65:913–919.
   PubMedGoogle Scholar
• Hutchinson M, Waters P, McHugh J, Gorman G, O'Riordan S, Connolly S, Hager H, Yu P, Becker CM, Vincent A. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology. 2008; 71:1291–1292.
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in “seronegative” myasthenia gravis. Brain. 2008; 131:1940–1952.
   PubMed Web of Science ®Google Scholar
• Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980; 103:579–601.
   PubMed Web of Science ®Google Scholar
• Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Different HLADR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990; 31:285–290.
   PubMed Web of Science ®Google Scholar
• Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol. 1993; 47:115–122.
   PubMed Web of Science ®Google Scholar
• Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W. Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci. 2003; 998:324–335.
   PubMed Web of Science ®Google Scholar
• Brueton LA, Huson SM, Cox PM, Shirley I, Thompson EM, Barnes PR, Price J, Newsom-Davis J, Vincent A. Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. Am J Med Genet. 2000; 92:1–6.
   PubMed Web of Science ®Google Scholar
• Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, Newsom-Davis J. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet. 1995; 346:24–25.
   PubMed Web of Science ®Google Scholar
• Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004; 24:101–110.
   Google Scholar
• Vincent A, Li Z, Hart A, Barrett-Jolley R, Yamamoto T, Burges J, Wray D, Byrne N, Molenaar P, Newsom-Davis J. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NY Acad Sci. 1993; 681:529–538.
   PubMed Web of Science ®Google Scholar
• Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol. 2008; 201–202:2–5.
   Google Scholar
• Engel AG, Shen XM, Selcen D, Sine SM. Further, observations in congenital myasthenic syndromes. Ann NY Acad Sci. 2008; 1132:104–113.
   PubMed Web of Science ®Google Scholar
• Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psych. 2003; 74:1105–1108.
   PubMed Web of Science ®Google Scholar
• Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005; 65:928–930.
   PubMed Web of Science ®Google Scholar
• Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Linkage of HLA to myasthenia gravis and genetic hetero: Geneity depending on anti-titin antibodies. Neurology. 2001; 57:1555–1560.
   PubMed Web of Science ®Google Scholar
• Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology. 2001; 57:1579–1582.
   PubMed Web of Science ®Google Scholar
• Niks EH, Kuks JB, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, De Baets MH, Vincent A, Verschuuren JJ. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006; 66:1772–1774.
   PubMed Web of Science ®Google Scholar
• Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005; 57:444–448.
   PubMed Web of Science ®Google Scholar
• Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol. 2007; 171:893–905.
   PubMedGoogle Scholar
• Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005; 64:536–538.
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology. 1978; 28:266–272.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci. 2008; 1132:305–314.
   PubMed Web of Science ®Google Scholar
• Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology. 1983; 33:1276–1282.
   PubMed Web of Science ®Google Scholar
• Farrugia ME, Melms A, Vincent A. Myasthenia gravis with MuSK antibodies. Pract Neurol. 2005; 5:356–359.
   Google Scholar
• Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology. 2006; 67:505–507.
   PubMed Web of Science ®Google Scholar
• Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E. Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol. 2008; 201–202:90–94.
   PubMed Web of Science ®Google Scholar
• Mygland A, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, Gilhus NE, Aarli JA. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000; 57:527–531.
   PubMedGoogle Scholar
• Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990; 82:284–288.
   PubMed Web of Science ®Google Scholar
• Mygland A, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol. 1992; 32:589–591.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, Suzuki N, Kuwana M. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005; 170:141–149.
   PubMed Web of Science ®Google Scholar
• Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol. 2000; 247:369–375.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Terayama Y, Suzuki N, Kuwana M. Classification of myasthenia gravis based on autoantibody status. Arch Neurol. 2007; 64:1121–1124.
   PubMedGoogle Scholar
• Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003; 132:128–136.
   PubMed Web of Science ®Google Scholar
• Ohta M, Ohta K, Mori F, Itoh N, Nishitani H, Hayashi K. Improved radioassay of anti-acetylcholine receptor antibody: Application for the detection of extremely low antibody titers in sera from patients with myasthenia gravis. Clin Chem. 1990; 36:911–913.
   Google Scholar
• Ricny J, Simkova L, Vincent A. Determination of anti-acetylcholine receptor antibodies in myasthenic patients by use of time-resolved fluorescence. Clin Chem. 2002; 48:549–554.
   Google Scholar
• Furukawa S, Akazawa S, Furukawa Y, Kamo I, Satoyoshi E, Hayashi K. A practical enzyme immunoassay for anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol. 1984; 6:397–409.
   PubMed Web of Science ®Google Scholar
• Gotti C, Balestra B, Mantegazza R, Tzartos S, Moretti M, Clementi F. Detection of antibody classes and subpopulations in myasthenia gravis patients using a new nonradioactive enzyme immunoassay. Muscle Nerve. 1997; 20:800–808.
   Google Scholar
• Franciotta D, Martino G, Brambilla E, Zardini E, Locatelli V, Bergami A, . TE671 cell-based ELISA for anti-acetylcholine receptor antibody determination in myasthenia gravis. Clin Chem. 1999; 45:400–405.
   PubMed Web of Science ®Google Scholar
• Sanders J, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010; 43:428–435.
   PubMed Web of Science ®Google Scholar